Meeting
2024 ASCO Breakthrough
Predicting chemotherapy response in patients with advanced or metastatic pancreatic cancer using machine learning.
Authors
Moonho Kim
Department of Hematology and Oncology, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, South Korea
Moonho Kim , Gyucheol Choi , Jamin Koo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies
Sub Track
Artificial Intelligence/Deep Learning
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 60)
DOI
10.1200/JCO.2024.42.23_suppl.60
Abstract #
60
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2019 ASCO Quality Care Symposium
Outcomes and care patterns for advanced pancreatic cancer patients treated in tertiary vs regional/community cancer centres in Northern Alberta.
First Author: Matthew Anaka
Poster
2018 Gastrointestinal Cancers Symposium
Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?
First Author: William Raskin
Poster
2016 ASCO Annual Meeting
Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): an Italian multicentre real life experience.
First Author: Guido Giordano